A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia

Leukemia Research

Volumn 34, Issue 12, 2010, Pages 1622-1626

  Advani, Anjali S ^a   Tiu, Ramon ^a   Saunthararajah, Yogen ^a   Maciejewski, Jaroslaw ^a   Copelan, Edward A ^a   Sobecks, Ronald ^a   Sekeres, Mikkael A ^a   Bates, Jennifer ^a   Rush, Mary Lynn ^a   Tripp, Barbara ^a   Salvado, August ^b   Noon, Elysa ^b   Howard, Matthew ^c   Jin, Tao ^c   Hsi, Eric ^c   Egorin, Merrill J ^d   Lim, Kathleen ^a   Cotta, Claudiu V ^c   Price, Courtney ^a   Kalaycio, Matt ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Acute myeloid leukemia; C Kit; Imatinib mesylate; Relapse; STAT5; Treatment

Indexed keywords

2 [2 METHYL 5 [4 (1 PIPERAZINYLMETHYL)BENZAMIDO]ANILINO] 4 (3 PYRIDYL)PYRIMIDINE; AMINOTRANSFERASE; ANTHRACYCLINE; CBL PROTEIN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; IMATINIB; MITOXANTRONE; STAT3 PROTEIN; STAT5 PROTEIN; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW BIOPSY; BONE PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLUID RETENTION; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; MUSCLE CRAMP; MUTATIONAL ANALYSIS; MYALGIA; NAUSEA; NECK PAIN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIDE EFFECT; VISUAL DISORDER; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DAUNORUBICIN; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PHOSPHORYLATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECURRENCE; STAT5 TRANSCRIPTION FACTOR;

EID: 78149350558     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.03.021     Document Type: Article

References (20)

1. Robak T., Wrzesien-Kus A. The search for optimal treatment in relapsed and refractory acute myeloid leukemia. Leukemia & Lymphoma 2002, 43:281-291.
2. Hans C.P., Finn W.G., Singleton T.P., Schnitzer B., Ross C.W. Usefulness of anti-CD117 in the flow cytometric analysis of acute leukemia. American Journal of Clinical Pathology 2002, 117:301-305.
3. Domen J., Weissman I. Hematopoietic stem cells need two signals to prevent apoptosis; BCL-2 can provide one of these, kitI/c-kit signaling the other. Journal of Experimental Medicine 2000, 192:1707-1708.
4. Del Poeta G, Venditti A., Del Principe M.I., Maurillo L., Buccisano F., Tamburini A., et al. Amount of spontaneous apoptosis detected by bax/bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 2003, 101:2125-2131.
5. Linnekin D. Early signaling pathways activated by c-kit in hematopoietic progenitor cells. International Journal of Biochemistry and Cell Biology 1999, 31:1053-1074.
6. Scheper H., van Gosliga D., Wierenga A.T., Eggen B.J., Schuringa J.J., Vellenga E. STAT5 is required for long-term maintenance of normal and leukemic human stem/progenitor cells. Blood 2007, 110:2880-2888.
7. Kindler T., Breitenbucher F., Marx A., Beck J., Hess G., Weinkauf B., et al. Efficacy and safety of imatinib in adult patients with c-kit positive acute myeloid leukemia. Blood 2004, 103:3644-3654.
8. Caligiuri M.A., Briesewitz R., Yu J., Wang L., Wei M., Arnoczky K.J., et al. The CBL ubiquitin ligase targets a variety of activated tyrosine kinases for degradation. Blood 2007, 110:1022-1024.
9. Masson K., Heiss E., Band H., Ronnstrand L. Direct binding of Cbl to Tyr568 and Tyr936 of the stem cell factor/c-kit is required for ligand-induced ubiquitination, internalization, and degradation. The Biochemical Journal 2006, 399:59-67.
10. Walker A., Komrokji R., Ifthikharuddin J., Messina J., Messina P., Mulford D., et al. Phase 1 study of cladribine, cytarabine (Ara-C), granulocyte stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. Leukemia Research 2008, 32(12):1830-1836.
11. Heidel F., Cortes J., Rucker F.G., Aulitzky W., Letvak L., Kindler T., et al. Results of a multicenter phase II trial for older patients with c-kit positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and imatinib. Cancer 2007, 109:907-914.
12. Fang G., Kim C., Perkins C., Ramadevi N., Winton E., Wittman S., et al. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive leukemia cells to apoptosis due to antileukemic drugs. Blood 2000, 96:2246-2253.
13. Bennett J.A., Riegel B., Bittner V., Nichols J. Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease. Heart & Lung 2002, 31:262-270.
14. Byrd J.C., Mrozek K., Dodge R.K., Carroll A.J., Edwards C.G., Arthur D.C., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100:4325-4336.
15. Advani A.S., Rodriguez C., Jin T., Jawde R.A., Saber W., Baz R., et al. Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML. Leukemia Research 2008, 32:913-918.
16. Dunbar A.J., Gondez L.P., O'Keefe C.L., Makishima H., Rataul M.S., Szpurka H., et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Research 2008, 68:10349-10357.
17. Parise R.A., Ramanathan R.K., Hayes M.J., Egorin M.J. Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. Journal of Chromatography B 2003, 791:39-44.
18. Cheson B.D., Bennett J.M., Kopecky K.J., Buchner T., Willman C.L., Estey E.H., et al. Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standardization for Therapeutic Trials in Acute Myeloid Leukemia. Journal of Clinical Oncology 2003, 24:4642-4649.
19. Ottmann O.G., Druker B.J., Sawyers C.L., Goldman J.M., Reiffers J., Silver R.T., et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002, 100:1965-1971.
20. Chevallier P., Delaunay J., Turlure P. Long term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapse acute myeloid leukemia. Journal of Clinical Oncology 2008, 26:5192-5197.